Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term Kidney cancer. Found 15 abstracts

Nejati R, Wei S, Uzzo RG, Poureghbali S, Pei J, Talarchek JN, Ruth K, Dulaimi E, Kutikov A, Testa JR, Al-Saleem T. Monosomy of Chromosome 9 Is Associated With Higher Grade, Advanced Stage, and Adverse Outcome in Clear-cell Renal Cell Carcinoma. Clin Genitourin Cancer. 2019 Sep 26;.
Liao L, Alicea-Velazquez NL, Langbein L, Niu X, Cai W, Cho EA, Zhang M, Greer CB, Yan Q, Cosgrove MS, Yang H. High affinity binding of H3K14ac through collaboration of bromodomains 2, 4 and 5 is critical for the molecular and tumor suppressor functions of PBRM1. Mol Oncol. 2018 Dec 26;.
Mir MC, Capitanio U, Bertolo R, Ouzaid I, Salagierski M, Kriegmair M, Volpe A, Jewett MA, Kutikov A, Pierorazio PM. Role of Active Surveillance for Localized Small Renal Masses. European urology oncology. 2018 Aug;1(3):177-87.
Chen VS, Abouassaly R, Gonzalez CM, Kutikov A, Smaldone MC, Meropol NJ, Psutka SP, Williams SB, O'Malley R, Sedlacek HM, Kim SP. Association of race and margin status among patients undergoing robotic partial nephrectomy for T1 renal cell carcinoma: Results from a population-based cohort. Urol Oncol. 2017 Nov;35(11):662 e17-662 e21.
Joshi SS, Uzzo RG. Renal Tumor Anatomic Complexity: Clinical Implications for Urologists. The Urologic clinics of North America. 2017 May;44(2):179-87.
Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma. Journal of translational medicine. 2017 Apr 06;15(1):72.   PMCID: PMC5383954
Lee HO, Uzzo RG, Kister D, Kruger WD. Combination of serum histidine and plasma tryptophan as a potential biomarker to detect clear cell renal cell carcinoma. Journal of translational medicine. 2017 Apr 06;15(1):72.   PMCID: PMC5383954
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.
Merza H, Bilusic M. Current Management Strategy for Metastatic Renal Cell Carcinoma and Future Directions. Current oncology reports. 2017 Apr;19(4):27.   PMCID: Review
Ristau BT, Correa AF, Uzzo RG, Smaldone MC. Active Surveillance for the Small Renal Mass: Growth Kinetics and Oncologic Outcomes. The Urologic clinics of North America. 2017 May;44(2):213-22.
Ristau BT, Kutikov A, Uzzo RG, Smaldone MC. Active Surveillance for Small Renal Masses: When Less is More. European urology focus. 2016 Dec 15;2(6):660-8.
Kiechle JE, Abouassaly R, Smaldone MC, Shah ND, Dong S, Cherullo EE, Nakamoto D, Zhu H, Cooney MM, Kim SP. National Trends of Local Ablative Therapy among Young Patients with Small Renal Masses in the United States. Urology. 2015 Sep;86(5):962-7.
Shuch B, Amin A, Armstrong AJ, Eble JN, Ficarra V, Lopez-Beltran A, Martignoni G, Rini BI, Kutikov A. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. Eur Urol. 2015 Jan;67(1):85-97.
Tomaszewski JJ, Kutikov A. Small renal mass management in the elderly and the calibration of risk. Urol Oncol. 2015 Apr 07;33(5):197-200.
Zibelman M, Barth P, Handorf E, Smaldone MC, Kutikov A, Uzzo RG, Bilusic M, Plimack ER, Wong YN, Geynisman DM. A review of interventional clinical trials in renal cell carcinoma: a status report from the ClinicalTrials.gov WebSite. Clin Genitourin Cancer. 2015 Apr;13(2):142-9.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term Kidney cancer

Last updated on Friday, January 03, 2020